This free sheet contains 100 accelerators and incubators you can apply to today, along with information about the industries they generally invest in.
This free sheet contains all the information about the top 100 unicorns, including their valuation, HQ's location, founded year, name of founders, funding amount and number of employees.
This free Notion document contains the best 100+ resources you need for building a successful startup, divided in 4 categories: Fundraising, People, Product, and Growth.
The Life Science sector is attracting large investments, with many new companies blending biology and artificial intelligence. These startups are addressing major challenges from drug discovery to genetic engineering.
Treeline Biosciences has secured over $1.1 billion for developing cancer treatments. Another company, Colossal Biosciences, is focused on de-extinction.
Below is our list of 100 Life Science startups worth keeping an eye on.
Everything you need to raise funding for your startup, including 3,500+ investors, 7 tools, 18 templates and 3 learning resources.
Buy It For $97 $297 →Information about the industries, countries, and cities they generally invest in.
Get the Sheet for $50Information about their valuation, HQ's location, founded year, name of founders, funding amount and number of employees.
Get the Sheet for $50List of startup investors in the BioTech, Health, and Medicine industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50List of 250 startup investors in the AI and Machine Learning industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50List of 250 startup investors in the FinTech and Finance industries, along with their Twitter, LinkedIn, and email addresses.
Get the Sheet for $50Using breakthrough gene-editing technology, Colossal Biosciences is working to de-extinct species like the woolly mammoth. Their efforts are also aimed at developing new tools for genomics and species conservation.
Lila Sciences is creating a scientific superintelligence platform and autonomous labs to advance research. Their work focuses on accelerating breakthroughs in life sciences, chemistry, and materials science.
CHARM Therapeutics develops small-molecule medicines targeting hard-to-treat cancers and other serious diseases. They apply a proprietary 3D deep learning platform to predict protein structures and accelerate the drug discovery process.
Cartography Biosciences creates cancer immunotherapies that precisely target novel tumor antigens. Their work in antigen cartography aims to develop safer, more effective treatments for a wide range of cancers.
Isomorphic Labs, an Alphabet company, is applying advanced AI to reimagine how new medicines are created. Their digital biology platform is designed to predict how drugs will interact with the body, accelerating the development of new treatments for disease.
Axtria develops data analytics software and offers services tailored to the life sciences industry. Their cloud platforms help organizations manage complex data and uncover insights that drive better commercial and patient outcomes.
Folia Health builds a platform for individuals to capture their own health and symptom data from home. The company's tools then organize these observations into structured information that can be shared with clinicians and researchers.
Treeline Biosciences develops transformative precision medicines for patients with cancer and other serious conditions. The biotech company is focused on pioneering new therapies that target the underlying drivers of disease.
Element Biosciences builds DNA sequencing technology for the research and diagnostics markets. Their flagship product, the AVITI System, is a benchtop sequencer that gives scientists more accessible tools for genetic analysis.
Kriya Therapeutics develops gene therapies to address highly prevalent diseases. The biopharmaceutical company's core focus is on treatments for ophthalmology, neurology, and metabolic conditions.
Our top 10 picks are just a small slice of the life science world. Combined, the companies on our full list have raised more than $12 billion to push their work forward.
Most of these companies work in biotech and AI, and they include both new founders and more established names. Here’s a look at the rest of the startups shaping the life science ecosystem.
| Startup | Main Industry | Year Founded | Amount Raised | Last Funding Round |
|---|---|---|---|---|
| Biotech | 2019 | $7.6M | Grant | |
| Biotech | 2016 | $600M | Venture Round | |
| Biotech | 2021 | $45.8M | Series A | |
| AI | 2017 | $98M | Venture Round | |
| AI | 2022 | $103.1M | Series A | |
| Biotech | 2015 | $30.2M | Series A | |
| Biotech | 2016 | $150.1M | Series C | |
| AI | 2023 | $13M | Seed | |
| Biotech | 2019 | $355M | Series C | |
| AI | 2014 | $129.8M | Series D | |
| Biotech | 2014 | $456M | Series D | |
| Biotech | 2018 | $127.3M | Series B | |
| Biotech | 2019 | $258M | Venture Round | |
| Biotech | 2017 | $257.2M | Series B | |
| Enterprise | 2019 | $40.1M | Series B | |
| Biotech | 2023 | $28.6M | Series A | |
| Biotech | 2017 | $120M | Convertible Note | |
| Biotech | 2013 | $25.7M | Venture Round | |
| Biotech | 2024 | $50M | Series A | |
| Healthcare | 2022 | $270M | Series A | |
| Biotech | 2020 | $46M | Series A | |
| AI | 2014 | $207M | Series C | |
| Biotech | 2020 | $13.8M | Grant | |
| Biotech | 2018 | $640.6M | Series D | |
| Biotech | 2013 | $271.3M | Series F | |
| AI | 2023 | $44.5M | Series A | |
| Biotech | 2018 | $346.1M | Series D | |
| Biotech | 2020 | $2.5B | Grant | |
| Biotech | 2020 | $117M | Series C | |
| Analytics | 2016 | $6.7M | Series A | |
| Biotech | 2018 | $100M | Series C | |
| Biotech | 2020 | $3.8M | Seed | |
| Biotech | 2019 | $52M | Series B | |
| Biotech | 1987 | $1.1B | Private Equity | |
| AI | 2023 | $16M | Series A | |
| AI | 2014 | $114.9M | Venture Round | |
| Biotech | 2020 | $247M | Series B | |
| Biotech | 2019 | $1.1B | Series D | |
| Biotech | 2019 | $149.1M | Venture Round | |
| Biotech | 2018 | $140.1M | Series B | |
| Biotech | 2020 | $315.2M | Venture Round | |
| Biotech | 2018 | $53.5M | Series A | |
| Healthcare | 2019 | $10M | Venture Round | |
| Biotech | 2018 | $207M | Series B | |
| AI | 2018 | $200M | Series B | |
| Biotech | 2020 | $365M | Corporate Round | |
| AI | 2018 | $15.1M | Series A | |
| Biotech | 2021 | $100M | Venture Round | |
| Biotech | 2011 | $150M | Debt Financing | |
| Biotech | 2021 | $26.5M | Grant | |
| AI | 2022 | $55M | Grant | |
| Design | 2017 | $17M | Series A | |
| Biotech | 2017 | $5.6M | Debt Financing | |
| Biotech | 2017 | $23M | Series B | |
| Biotech | 2018 | $6.3M | Seed | |
| Biotech | 2018 | $643M | Series C | |
| AI | 2023 | $50M | Series A | |
| AI | 2021 | $102.7M | Series B | |
| AI | 2021 | $110M | Venture Round | |
| Biotech | 2018 | $15.5M | Seed | |
| Biotech | 2016 | £128M | Series B | |
| Biotech | 2013 | $27.8M | Venture Round | |
| AI | 2017 | $244.4M | Series C | |
| Biotech | 2016 | $304.5M | Series C | |
| Analytics | 2013 | $11.2M | Series A | |
| Biotech | 2022 | $12M | Seed | |
| AI | 2020 | $447M | Series D | |
| AI | 2013 | $228.6M | Venture Round | |
| Biotech | 2018 | $7.5M | Seed | |
| Healthcare | 2022 | $26.2M | Seed | |
| Biotech | 2014 | $41.5M | Venture Round | |
| Biotech | 2021 | $100M | Series A | |
| Biotech | 2021 | $44.8M | Seed | |
| Biotech | 2003 | $183.3M | Grant | |
| Biotech | 2019 | $630.8M | Series C | |
| Biotech | 2017 | $59.5M | Series A | |
| AI | 2021 | $6.7M | Seed | |
| Biotech | 2019 | $164.2M | Undisclosed | |
| Biotech | 2018 | $128.6M | Series B | |
| Biotech | 2017 | £60M | Series B | |
| Biotech | 2000 | $11.7M | Convertible Note | |
| Biotech | 2018 | $22.7M | Venture Round | |
| Biotech | 2021 | $331M | Series B | |
| AI | 2017 | $134.9M | Series C | |
| AI | 2016 | $147M | Undisclosed | |
| Biotech | 2022 | $242M | Series B | |
| Biotech | 2017 | $43.6M | Series A | |
| Healthcare | 2017 | $55M | Series B | |
| Biotech | 1993 | $150M | Series A | |
| Security | 2017 | $37.6M | Series A |
